Pediatrix Medical Group, Inc. (BMV:MD)
Mexico · Delayed Price · Currency is MXN | Market Cap | 29.99B +26.6% |
| Revenue (ttm) | 34.82B -2.3% |
| Net Income | 3.14B |
| EPS | 37.22 |
| Shares Out | n/a |
| PE Ratio | 9.55 |
| Forward PE | 9.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,800 |
| Average Volume | 4,229 |
| Open | 323.00 |
| Previous Close | 297.00 |
| Day's Range | 323.00 - 323.00 |
| 52-Week Range | 280.00 - 329.84 |
| Beta | 0.71 |
| RSI | 49.30 |
| Earnings Date | May 5, 2026 |
About Pediatrix Medical Group
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fe... [Read more]
News
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Passkey Therapeutics Appoints Mandeep Kaur, MD, MS, as Chief Medical Officer to Advance Clinical Validation of Its Computational Genetics-Based Novel Drug Combination Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Passkey Therapeutics, the architect of the Locksmith® platform for systematically identifying new therapeutic opportunities from synergistic drug combinations, today...
Pediatrix Medical price target raised to $25 from $22 at UBS
UBS raised the firm’s price target on Pediatrix Medical (MD) to $25 from $22 and keeps a Neutral rating on the shares.
Pediatrix Medical Group Q1 Earnings Call Highlights
Pediatrix Medical Group NYSE: MD reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported by higher pricing, improved collec...
Pediatrix Medical price target raised to $24 from $21 at Mizuho
Mizuho raised the firm’s price target on Pediatrix Medical (MD) to $24 from $21 and keeps a Neutral rating on the shares.
Pediatrix Medical Group Earnings Call Transcript: Q1 2026
Q1 delivered strong adjusted EBITDA of $58M, driven by 4% pricing growth and favorable payer mix, offsetting modest volume declines. Full-year adjusted EBITDA guidance of $280M–$300M is reaffirmed, with pricing expected to remain flat as RCM cash collection impact tapers.
Pediatrix Medical Group Quarterly report: Q1 2026
Pediatrix Medical Group has published its Q1 2026 quarterly earnings report on May 5, 2026.
Pediatrix Medical Group Earnings release: Q1 2026
Pediatrix Medical Group released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Pediatrix Medical reaffirms FY26 adjusted EBITDA view $280M-$300M
06:10 EDT Pediatrix Medical (MD) reaffirms FY26 adjusted EBITDA view $280M-$300M
Pediatrix Medical Group Reports First Quarter Results
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports First Quarter Results.
Ambience Healthcare Appoints Michael Han, MD, MBA as Chief Medical Officer
SAN FRANCISCO--(BUSINESS WIRE)--Ambience Healthcare, the leading AI platform for clinical documentation and revenue integrity, today announced the appointment of Michael Han, MD, MBA as Chief Medical ...
Pediatrix Medical price target raised to $27 from $24 at Jefferies
Jefferies analyst Jack Slevin raised the firm’s price target on Pediatrix Medical (MD) to $27 from $24 and keeps a Buy rating on the shares. The relative underperformance of healthcare…
Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026.
Pediatrix Medical Group Proxy statement: Proxy filing
Pediatrix Medical Group filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Pediatrix Medical price target raised to $23 from $21 at Truist
Truist raised the firm’s price target on Pediatrix Medical (MD) to $23 from $21 and keeps a Hold rating on the shares as part of a broader research note previewing…
Pediatrix Medical Group Proxy statement: Proxy filing
Pediatrix Medical Group filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Pediatrix Medical Group Proxy statement: Proxy filing
Pediatrix Medical Group filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Expands Maternal Health Services in Tennessee in Partnership with Tennessee Maternal-Fetal Medicine.
Pediatrix Welcomes Two Nationally Renowned Physician Leaders
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Welcomes Two Nationally Renowned Physician Leaders.
Pediatrix Medical price target lowered to $22 from $23 at UBS
UBS analyst AJ Rice lowered the firm’s price target on Pediatrix Medical (MD) to $22 from $23 and keeps a Neutral rating on the shares. The ACA headwind remains a…
Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology.
Pediatrix Medical price target lowered to $19 from $21 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Pediatrix Medical (MD) to $19 from $21 and keeps a Hold rating on the shares. The firm says the company’s volumes were…
Pediatrix Medical price target lowered to $21 from $24 at Truist
Truist lowered the firm’s price target on Pediatrix Medical (MD) to $21 from $24 and keeps a Hold rating on the shares. The firm maintained its Hold view following Q4…
Pediatrix Medical Group Earnings Call Transcript: Q4 2025
Q4 2025 capped a strong year with adjusted EBITDA of $66M and full-year $276M, driven by favorable payer mix, acuity, and disciplined cost control. 2026 guidance projects flat revenue at $1.9B and 5% EBITDA growth, with steady operational metrics and no M&A included.
Pediatrix Medical Group Earnings release: Q4 2025
Pediatrix Medical Group released its Q4 2025 earnings on February 19, 2026, summarizing the period's financial results.